
DarioHealth (DRIO) Stock Forecast & Price Target
DarioHealth (DRIO) Analyst Ratings
Bulls say
DarioHealth is a leading digital therapeutics company, with a vertically integrated health intelligence platform that is driving strong clinical outcomes and sustained engagement. The company's transition to the enterprise end-markets is showing signs of success and is expected to lead to share gains, earnings revision, and multiple expansion. Despite facing challenges with revenue growth and cost management, the company's focus on expanding its pipeline and partnerships, as well as its improving cost structure, make it a strong investment opportunity in the digital health industry.
Bears say
DarioHealth is a virtual chronic care company, founded in 2011, with a recent focus on B2B2C solutions that utilize connected devices, personalized engagement, and digital and human coaching. While the company has seen success in expanding its reach through partnerships and new accounts, currently in the contracting phase with its largest partner to date, its financials show a growing revenue of $25.5 million in 2026 and $40.5 million in 2027, but with a projected adj. EBITDA of ($16.7 million) and ($3 million) respectively, causing a negative outlook for the stock.
This aggregate rating is based on analysts' research of DarioHealth and is not a guaranteed prediction by Public.com or investment advice.
DarioHealth (DRIO) Analyst Forecast & Price Prediction
Start investing in DarioHealth (DRIO)
Order type
Buy in
Order amount
Est. shares
0 shares